Passage Net Receivables from 2010 to 2026
| PASG Stock | USD 9.11 1.46 13.81% |
Net Receivables | First Reported 2010-12-31 | Previous Quarter 3.8 M | Current Value 4.9 M | Quarterly Volatility 1.7 M |
Check Passage Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Passage Bio's main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.53. Passage financial statements analysis is a perfect complement when working with Passage Bio Valuation or Volatility modules.
Passage | Net Receivables | Build AI portfolio with Passage Stock |
The Net Receivables trend for Passage Bio offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Passage Bio is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Passage Bio's Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Passage Bio over the last few years. It is Passage Bio's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Passage Bio's overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Passage Net Receivables Regression Statistics
| Arithmetic Mean | 6,829,273 | |
| Geometric Mean | 6,581,766 | |
| Coefficient Of Variation | 25.48 | |
| Mean Deviation | 1,552,588 | |
| Median | 8,029,000 | |
| Standard Deviation | 1,740,116 | |
| Sample Variance | 3T | |
| Range | 4.2M | |
| R-Value | (0.83) | |
| Mean Square Error | 1T | |
| R-Squared | 0.68 | |
| Significance | 0.000046 | |
| Slope | (284,292) | |
| Total Sum of Squares | 48.4T |
Passage Net Receivables History
About Passage Bio Financial Statements
Passage Bio stakeholders use historical fundamental indicators, such as Passage Bio's Net Receivables, to determine how well the company is positioned to perform in the future. Although Passage Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Passage Bio's assets and liabilities are reflected in the revenues and expenses on Passage Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Passage Bio. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 3.8 M | 4.9 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Passage Bio Correlation against competitors. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Can Biotechnology industry sustain growth momentum? Does Passage have expansion opportunities? Factors like these will boost the valuation of Passage Bio. Anticipated expansion of Passage directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Passage Bio demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Passage Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Passage Bio's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Passage Bio's market price to deviate significantly from intrinsic value.
It's important to distinguish between Passage Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Passage Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Passage Bio's market price signifies the transaction level at which participants voluntarily complete trades.